Stay ahead with the EMEA Thought Leadership insights: your source for industry-leading expertise and analysis
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases & Vaccines
- Oncology & Hematology
- Pediatrics
- Rare Diseases
- View All
Obesity
"Advancing obesity and obesity-related trials with patients at the center of development.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS
- Real World & Healthcare Data
- Health Data Apps & AI
- Analytics Research Accelerator
- Expert Ecosystem
- AI Patient & HCP Profiling- Commercial
- AI Patient & Provider Profiling- Med Affairs
- AI Patient & HCP Profiling- Healthcare
- Natural Language Processing
- Market Access Insights
- Direct-to-Patient Research
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI®
-
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESWhite Paper
Expanding the toolbox for obesity prevention and treatment in low- and middle-income countries: What does it take to make it happen?
Sep 26, 2025
Obesity is growing rapidly and contributing to serious and life-altering noncommunicable conditions, including diabetes, cardiovascular diseases, and some types of cancer. Historically, public health strategies to prevent and manage obesity have focused on behavioral and policy interventions promoting healthier lifestyles and discouraging the consumption of unhealthy foods. More recently, anti-obesity medicines (AOMs) have emerged as a valuable addition to the treatment toolkit, offering the added benefit of addressing related comorbidities. With some AOMs losing exclusivity and growing recognition of their public health value, supported by expanding clinical and real-world evidence and their inclusion in essential medicines lists (EMLs), their introduction and broader use in low- and middle-income countries (LMICs) could be transformative.
This white paper explores the implications of introducing AOMs in LMICs, focusing on:
- The current state of obesity as a public health threat in vulnerable regions.
- The opportunities and challenges these therapies present for prevention and treatment.
- The potential impact that affordable AOMs at scale—led by but not limited to off-patent semaglutide—could generate in LMICs.
- Strategic pathways for governments, life sciences companies, and multilateral organizations to improve access and health system readiness.
The paper concludes with a reflection on the value of using real-world data, especially through obesity registries, to encourage more inclusive clinical research, evaluate the success and sustainability of treatment, and support the refinement of policies and other public interventions.